The Patent Finder

Terms ending in 2039

Eyepoint, Inc.

Every in-force patent on Eyepoint, Inc.'s record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
PatentTitleHolderStatusExpiresConfidence
US 12,329,859Bioerodible Drug Delivery Devices
In force
 · Medium confidence
Eyepoint Pharmaceuticals, Inc.In forceMedium confidence
US 12,514,823Bioerodible Drug Delivery Devices
In force
 · Medium confidence
Eyepoint Pharmaceuticals, Inc.In forceMedium confidence
US 10,894,824Multispecific Antibodies That Target Hptp-B (VE-PTP) and VEGF
In force
 · High confidence
Eyepoint, Inc.In forceHigh confidence
US 11,873,334Method of Treating Ocular Conditions by Administering an Antibody That Activates TIE2 and Binds VEGF
In force
 · High confidence
Eyepoint, Inc.In forceHigh confidence
US 12,398,204Method of Treating an Ocular Condition by Administering Multispecific Antibodies That Activates TIE2 and Binds a Receptor Tyrosine Kinase Agonist
In force
 · High confidence
Eyepoint, Inc.In forceHigh confidence
5 of 5 patents shown. Soonest term end first, then patent number.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited